Survodutide advances metabolic disease treatment, while biosimilar capacity expands, FDA delays hemophilia review, and lupus data support next steps.
|Articles|November 1, 2019
- BioPharm International-11-01-2019
- Volume 32
- Issue 11
Zippered Lab Coat
Kimberly-Clark Professional introduced the Kimtech A8 Zippered Lab Coat for liquid and particle protection for ISO 7 and 8 or higher cleanroom environments.
Advertisement
Kimberly-Clark Professional introduced the Kimtech A8 Zippered Lab Coat for liquid and particle protection for ISO 7 and 8 or higher cleanroom environments.
In response to customer requests for a more secure closure, the company equipped the new lab coat with a nylon zipper and no-pocket design, rather than the typical snap design, which runs the risk of contamination to people and processes because of gaps between the closures and the possibility of the snaps falling off, according to a company press release.
The lab coat is available in sizes small to 6XL with anti-static three-layer spunbond meltblown spunbond fabric, a mandarin collar for added protection, and soft knit cuffs. It can also be recycled through The RightCycle Program, a recycling program for non-hazardous lab, cleanroom, and industrial waste.
Articles in this issue
almost 7 years ago
Biopharma modeling, now and five years from nowalmost 7 years ago
A Diverse Landscape of Patent Issues Seen in the US, UK, and the EUalmost 7 years ago
Modeling Comes of Age in Biopharmaalmost 7 years ago
Applying Lessons Learned from the Semiconductor Industryalmost 7 years ago
What’s New in Manufacturing: Downstream Technologiesalmost 7 years ago
KUBio Box for Viral Vectorsalmost 7 years ago
More Consistent Drug Inspection System on Horizonalmost 7 years ago
Signatures–What’s in a Name?almost 7 years ago
Modernizing Flu Vaccine ManufacturingAdvertisement
Related to this article
Litifilimab extended skin responses through 52 weeks in phase 2 AMETHYST data in cutaneous lupus erythematosus, with phase 3 results expected in 2027.
Manufacturing remediation, not efficacy or safety data, is delaying US approval of Novo's h+emophilia A therapy denecimig.
Doubled drug substance capacity at Alvotech's Reykjavik, Iceland, site aims to secure steady US supply of the Humira biosimilar Simlandi.
The glucagon/GLP-1 dual agonist hit both weight loss endpoints in phase 3, though gastrointestinal discontinuations and competitor data temper the readout.
CaseBioscience joins an ARPA-H effort to develop room-temperature cell therapy preservation, Novartis licenses an mRNA-encoded T-cell engager from Abogen, and AstraZeneca, Daiichi Sankyo, and Summit plan to combine Datroway with ivonescimab.
LumaLex Law's Dustin Robinson explains why retatrutide compounding remains illegal regardless of the Seventh Circuit's pending classification ruling.
Artiva Biotherapeutics will present data on AlloNK, an allogeneic, non-genetically modified NK cell therapy given with rituximab, in refractory rheumatoid arthritis, Sjögren disease and systemic sclerosis at ACR Convergence 2026, ahead of a planned phase 3 trial in rheumatoid arthritis.
Advertisement
Advertisement